Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 trial)

被引：102

作者：

Januzzi, JL

Cannon, CP

DiBattiste, PM

Murphy, S

Weintraub, W

Braunwald, E

机构：

[1] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA

[2] Merck Res Labs, West Point, PA USA

[3] Emory Univ, Atlanta, GA 30322 USA

[4] Brigham & Womens Hosp, Boston, MA 02115 USA

[5] TIMI Study Grp, Boston, MA USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 90卷 / 11期

关键词：

D O I：

10.1016/S0002-9149(02)02844-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Among patients in the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-Thrombolysis In Myocardial Infarction (TIMI) 18 study, decreasing renal function was associated with an increased prevalence of high-risk clinical findings, more extensive coronary artery disease, and independently associated with a high rate of adverse ischemic events after non-ST-segment elevation acute coronary syndrome (NSTE ACS). Across the range of renal function among patients in TACTICS-TIMI 18, the use of tirofiban plus an early invasive strategy was superior to conservative, ischemia-guided NSTE ACS management.

引用

页码：1246 / +

页数：5

共 13 条

[11] Development of a risk adjustment mortality model using the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000 [J].